Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUNARIZINE HCL

All products: Limited Use (codes 60, 61, 62)

Flunarizine · DIN 02246082 · 5mg · capsule

Limited Use — Reason for Use code 60, 61, 62 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 60, 61, 62 required
Write on scriptLU code 60, 61, 62 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 60, 61, 62
Reason for Use code 60 For patients with migraine headaches who have not responded to propranolol. Coverage limit: LU Authorization Period: 1 year Reason for Use code 61 For patients who have tried propranolol and experienced significant adverse effects. Coverage limit: LU Authorization Period: 1 year Reason for Use code 62 For patients in whom propranolol is contraindicated. Coverage limit: Contraindicated in patients with clinical depression and in patients with extrapyramidal disorders. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Flunarizine · DIN 02246082 Manufacturer: A A Pharma Inc.; listing date 2003-01-30 Health Canada: Marketed since 2011-12-01 · brand FLUNARIZINE · ATC N07CA03 FLUNARIZINE, N07CA03 FLUNARIZINE · form Capsule · route Oral · ingredients FLUNARIZINE (FLUNARIZINE HYDROCHLORIDE) 5 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Flunarizine: Formulary list price $0.8503/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8503 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70217 · Verify on the e-Formulary ↗ (DIN 02246082)

Source record
DIN 02246082: Flunarizine Raw flags: sec12=Y, sec3=Y Item: 920000216; group id 917; item number 2190; lccId 00127; manufacturer id AAP Source form: Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8503; ministry $0.8503 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246082 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70217
Interchangeable products
Sibelium · DIN 00846341 · not recorded
Shortage status: resolved shortage (ended 2025-06-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246082
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS FLUNARIZINE (flunarizine hydrochloride) is indicated for:  Prophylaxis of migraine (with and without aura) in patients with frequent and severe attacks, who have not responded satisfactorily to other treatment and/or in whom other therapy has resulted in unacceptable side effects. FLUNARIZINE is not indicated for the treatment of acute attacks. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLUNARIZINE in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use See 7.1.3 Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): The safety and efficacy of FLUNARIZINE in the prophylaxis of migraine has not been established in elderly subjects. See 7.1.4 Geriatrics, 8.2 Clinical Trial Adverse Reaction and 10.3 Pharmacokinetics, Geriatrics. https://pdf.hres.ca/dpd_pm/00064788.PDF PM date: August 8, 2002 Source product: FLUNARIZINE; DIN 02246082; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.